Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03464136




Registration number
NCT03464136
Ethics application status
Date submitted
7/03/2018
Date registered
13/03/2018
Date last updated
5/06/2023

Titles & IDs
Public title
Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year
Scientific title
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to That of Adalimumab in the Treatment of Biologic Naïve Subjects With Moderately-to-Severely Active Crohn's Disease
Secondary ID [1] 0 0
2017-004209-41
Secondary ID [2] 0 0
CR108449
Universal Trial Number (UTN)
Trial acronym
SEAVUE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Crohn Disease 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Inflammatory bowel disease
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 0 0 0 0
Crohn's disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Placebo for Ustekinumab
Treatment: Other - Placebo for Adalimumab
Treatment: Other - Ustekinumab (6 mg/kg)
Treatment: Other - Ustekinumab (90 mg)
Treatment: Other - Adalimumab (40 mg)

Experimental: Group 1 (Ustekinumab) - Participants will receive intravenous (IV) infusion of ustekinumab (approximately 6 milligram/kilogram \[mg/kg\]) and 4 subcutaneous (SC) injections of placebo for adalimumab at Week 0, followed by 2 SC injections of placebo at Week 2. From Week 4 to Week 56, participants will self-administer one SC injection of ustekinumab 90 milligram (mg) every 8 weeks (q8w) starting at Week 8 and placebo adalimumab at the other designated every 2 weeks (q2w) dosing intervals.

Active comparator: Group 2 (Adalimumab) - Participants will receive IV infusion of placebo for ustekinumab and 4 SC injections of adalimumab (each 40 mg, total dose 160 mg) at Week 0, followed by 2 SC injections of adalimumab (each 40 mg, total dose 80 mg) at Week 2. From Week 4 to Week 56, participants will self-administer 1 SC injection of adalimumab 40 mg q2w.


Treatment: Other: Placebo for Ustekinumab
Participants will receive placebo as SC injection to blind adalimumab.

Treatment: Other: Placebo for Adalimumab
Participants will receive placebo as IV infusion to blind ustekinumab.

Treatment: Other: Ustekinumab (6 mg/kg)
Participants will receive ustekinumab 6 mg/kg (weight based dosing) as IV infusion.

Treatment: Other: Ustekinumab (90 mg)
Participants will self-administer SC injection of ustekinumab 90 mg.

Treatment: Other: Adalimumab (40 mg)
Participants will self-administer multiple SC injections of adalimumab (each 40 mg) and will receive total dose of 160 mg at Week 0, 80 mg at Week 2, and 40 mg q2w from Week 4 to 56.
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Clinical Remission at Week 52
Timepoint [1] 0 0
Week 52
Secondary outcome [1] 0 0
Percentage of Participants With Corticosteroid-free Remission at Week 52
Timepoint [1] 0 0
Week 52
Secondary outcome [2] 0 0
Percentage of Participants With Clinical Response at Week 52
Timepoint [2] 0 0
Week 52
Secondary outcome [3] 0 0
Percentage of Participants in Patient Reported Outcome (PRO)-2 Symptom Remission at Week 52
Timepoint [3] 0 0
Week 52
Secondary outcome [4] 0 0
Percentage of Participants With Clinical Remission at Week 16
Timepoint [4] 0 0
Week 16
Secondary outcome [5] 0 0
Percentage of Participants With Endoscopic Remission at Week 52
Timepoint [5] 0 0
Week 52
Secondary outcome [6] 0 0
Percentage of Participants With Clinical Remission Through Week 52
Timepoint [6] 0 0
Weeks 2, 8, 16, 24, 32, 40, 48, and 52
Secondary outcome [7] 0 0
Percentage of Participants With Clinical Response Through Week 52
Timepoint [7] 0 0
Weeks 2, 8, 16, 24, 32, 40, 48, and 52
Secondary outcome [8] 0 0
Percentage of Participants With Durable Clinical Response at Week 52
Timepoint [8] 0 0
Week 52
Secondary outcome [9] 0 0
Percentage of Participants With Durable Clinical Remission at Week 52
Timepoint [9] 0 0
Week 52
Secondary outcome [10] 0 0
Percentage of Participants With Abdominal Pain (AP) Improvement Through Week 52
Timepoint [10] 0 0
Weeks 2, 8, 16, 24, 32, 40, 48, and 52
Secondary outcome [11] 0 0
Percentage of Participants With Reduction in Frequency of Diarrhea Through Week 52
Timepoint [11] 0 0
Weeks 2, 8, 16, 24, 32, 40, 48, and 52
Secondary outcome [12] 0 0
Percentage of Participants With Clinical and Biomarker Remission at Weeks 8, 16 and 52
Timepoint [12] 0 0
At Weeks 8, 16 and 52
Secondary outcome [13] 0 0
Percentage of Participants With Adverse Events (AEs)
Timepoint [13] 0 0
Up to Week 52 and up to Week 76
Secondary outcome [14] 0 0
Percentage of Participants With Infections
Timepoint [14] 0 0
Up to Week 52 and up to Week 76
Secondary outcome [15] 0 0
Percentage of Participants With Serious Infections
Timepoint [15] 0 0
Up to Week 52 and up to Week 76
Secondary outcome [16] 0 0
Percentage of Participants With Serious Adverse Events (SAEs)
Timepoint [16] 0 0
Up to Week 52 and up to Week 76
Secondary outcome [17] 0 0
Percentage of Participants With Anti-drug Antibodies
Timepoint [17] 0 0
Up to Week 52

Eligibility
Key inclusion criteria
* Has Crohn's Disease (CD) or fistulizing CD of at least 3 months' duration, with colitis, ileitis, or ileocolitis, confirmed at some time in the past by radiography, histology, and/or endoscopy
* Has moderately-to-severely active CD with a baseline Crohn's disease activity index (CDAI) score of greater than or equal to (>=) 220 and less than or equal to (<=) 450
* Has one or more ulceration on screening ileocolonoscopy (which by definition, would result in an Simple Endoscopic Score for Crohn's Disease [SES-CD] of at least 3)
* Has failed or was intolerant to conventional therapy (corticosteroids, azathioprine [AZA], 6-mercaptopurine [6-MP] and/or methotrexate [MTX]) at adequate doses or is corticosteroid dependent
* Has not previously received an approved biologic for Crohn's Disease (i.e., infliximab, adalimumab, certolizumab pegol, ustekinumab, natalizumab, vedolizumab or approved biosimilars of these agents)
* Participants on oral corticosteroids (e.g., prednisone, budesonide) at a prednisone-equivalent dose of <=40 or milligram/day (mg/day) or <=9 mg/day of budesonide are budesonide <=9 mg/day are permitted if doses are stable for 3 weeks prior to baseline
* Participants on AZA, 6-MP, or MTX at screening (or recently prior), must discontinue these medications at least 3 weeks prior to baseline
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Has complications of CD that are likely to require surgery or would confound the ability to assess the effect of ustekinumab or adalimumab treatment using the CDAI, such as: active stoma; short-gut syndrome and severe or symptomatic strictures or stenosis
* Currently has, or is suspected to have, an abscess. Recent cutaneous and perianal abscesses are not exclusionary if drained and adequately treated at least 3 weeks prior to baseline, or 8 weeks prior for intra-abdominal abscesses, if there is no anticipated need for any further surgery. Participants with active fistulas may be included if there is no anticipation of a need for surgery and there are currently no abscesses present
* Has had any kind of bowel resection within 6 months prior to baseline or other intra-abdominal surgery or a hospital admission for bowel obstruction within 3 months prior to baseline
* Has a stool culture or other examination positive for an enteric pathogen, including Clostridium difficile toxin, in the last 4 months unless a repeat examination is negative and there are no signs of ongoing infection with that pathogen
* Has received a Bacillus Calmette-Guerin (BCG) vaccination within 12 months or any other live bacterial or live viral vaccination within 2 weeks of baseline
* Has a history of, or ongoing, chronic or recurrent infectious disease, including but not limited to, chronic renal infection, chronic chest infection, recurrent urinary tract infection (eg, recurrent pyelonephritis or chronic nonremitting cystitis), or infected skin wounds or ulcers

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
29/03/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
21/05/2021
Sample size
Target
Accrual to date
Final
386
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Monash Health, Monash Medical Centre - Clayton
Recruitment hospital [2] 0 0
Alfred Hospital - Melbourne
Recruitment hospital [3] 0 0
Mater Hospital Brisbane (Inflammatory Bowel Diseases) - South Brisbane
Recruitment hospital [4] 0 0
St John of God Subiaco Hospital - Subiaco
Recruitment hospital [5] 0 0
The Queen Elizabeth Hospital - Woodville South
Recruitment postcode(s) [1] 0 0
3168 - Clayton
Recruitment postcode(s) [2] 0 0
3004 - Melbourne
Recruitment postcode(s) [3] 0 0
4101 - South Brisbane
Recruitment postcode(s) [4] 0 0
6008 - Subiaco
Recruitment postcode(s) [5] 0 0
5011 - Woodville South
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Idaho
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Kentucky
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Michigan
Country [14] 0 0
United States of America
State/province [14] 0 0
Minnesota
Country [15] 0 0
United States of America
State/province [15] 0 0
Missouri
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
North Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
North Dakota
Country [19] 0 0
United States of America
State/province [19] 0 0
Ohio
Country [20] 0 0
United States of America
State/province [20] 0 0
Oklahoma
Country [21] 0 0
United States of America
State/province [21] 0 0
Pennsylvania
Country [22] 0 0
United States of America
State/province [22] 0 0
South Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
Tennessee
Country [24] 0 0
United States of America
State/province [24] 0 0
Texas
Country [25] 0 0
United States of America
State/province [25] 0 0
Virginia
Country [26] 0 0
United States of America
State/province [26] 0 0
Washington
Country [27] 0 0
Belgium
State/province [27] 0 0
Gent
Country [28] 0 0
Belgium
State/province [28] 0 0
Leuven
Country [29] 0 0
Belgium
State/province [29] 0 0
Tournai
Country [30] 0 0
Brazil
State/province [30] 0 0
Belo Horizonte - MG
Country [31] 0 0
Brazil
State/province [31] 0 0
Goiania
Country [32] 0 0
Brazil
State/province [32] 0 0
Juiz de Fora
Country [33] 0 0
Brazil
State/province [33] 0 0
Porto Alegre
Country [34] 0 0
Brazil
State/province [34] 0 0
Ribeirao Preto
Country [35] 0 0
Brazil
State/province [35] 0 0
Rio de Janeiro
Country [36] 0 0
Brazil
State/province [36] 0 0
Santo Andre
Country [37] 0 0
Bulgaria
State/province [37] 0 0
Pleven
Country [38] 0 0
Bulgaria
State/province [38] 0 0
Rousse
Country [39] 0 0
Bulgaria
State/province [39] 0 0
Sofia
Country [40] 0 0
Bulgaria
State/province [40] 0 0
Varna
Country [41] 0 0
Canada
State/province [41] 0 0
Alberta
Country [42] 0 0
Canada
State/province [42] 0 0
Ontario
Country [43] 0 0
Canada
State/province [43] 0 0
Quebec
Country [44] 0 0
Czechia
State/province [44] 0 0
Brno
Country [45] 0 0
Czechia
State/province [45] 0 0
Horovice
Country [46] 0 0
Czechia
State/province [46] 0 0
Hradec Kralove
Country [47] 0 0
Czechia
State/province [47] 0 0
Praha 10
Country [48] 0 0
Czechia
State/province [48] 0 0
Praha 9
Country [49] 0 0
France
State/province [49] 0 0
Amiens
Country [50] 0 0
France
State/province [50] 0 0
Montpellier
Country [51] 0 0
France
State/province [51] 0 0
Nantes
Country [52] 0 0
France
State/province [52] 0 0
Paris
Country [53] 0 0
France
State/province [53] 0 0
Saint Priest en jarez
Country [54] 0 0
France
State/province [54] 0 0
Toulouse
Country [55] 0 0
Germany
State/province [55] 0 0
Freiburg
Country [56] 0 0
Germany
State/province [56] 0 0
Hamburg
Country [57] 0 0
Germany
State/province [57] 0 0
Heidelberg
Country [58] 0 0
Germany
State/province [58] 0 0
Muenster
Country [59] 0 0
Hungary
State/province [59] 0 0
Budapest
Country [60] 0 0
Hungary
State/province [60] 0 0
Békéscsaba
Country [61] 0 0
Hungary
State/province [61] 0 0
Debrecen
Country [62] 0 0
Hungary
State/province [62] 0 0
Miskolc
Country [63] 0 0
Hungary
State/province [63] 0 0
Szombathely
Country [64] 0 0
Italy
State/province [64] 0 0
Bologna
Country [65] 0 0
Italy
State/province [65] 0 0
Messina
Country [66] 0 0
Italy
State/province [66] 0 0
Milano
Country [67] 0 0
Italy
State/province [67] 0 0
Padova
Country [68] 0 0
Italy
State/province [68] 0 0
Palermo
Country [69] 0 0
Italy
State/province [69] 0 0
RHO
Country [70] 0 0
Italy
State/province [70] 0 0
Roma
Country [71] 0 0
Italy
State/province [71] 0 0
Rozzano
Country [72] 0 0
Italy
State/province [72] 0 0
Torino
Country [73] 0 0
Korea, Republic of
State/province [73] 0 0
Daegu
Country [74] 0 0
Korea, Republic of
State/province [74] 0 0
Gyeonggi-do
Country [75] 0 0
Korea, Republic of
State/province [75] 0 0
Seongnam-si
Country [76] 0 0
Korea, Republic of
State/province [76] 0 0
Seoul
Country [77] 0 0
Netherlands
State/province [77] 0 0
Amsterdam
Country [78] 0 0
Netherlands
State/province [78] 0 0
Arnhem
Country [79] 0 0
Netherlands
State/province [79] 0 0
Groningen
Country [80] 0 0
Netherlands
State/province [80] 0 0
Leiden
Country [81] 0 0
Netherlands
State/province [81] 0 0
Nijmegen
Country [82] 0 0
Netherlands
State/province [82] 0 0
Rotterdam
Country [83] 0 0
Poland
State/province [83] 0 0
Bialystok
Country [84] 0 0
Poland
State/province [84] 0 0
Gdansk
Country [85] 0 0
Poland
State/province [85] 0 0
Krakow
Country [86] 0 0
Poland
State/province [86] 0 0
Lodz
Country [87] 0 0
Poland
State/province [87] 0 0
Lublin
Country [88] 0 0
Poland
State/province [88] 0 0
Rzeszow
Country [89] 0 0
Poland
State/province [89] 0 0
Sopot
Country [90] 0 0
Poland
State/province [90] 0 0
Warsaw
Country [91] 0 0
Poland
State/province [91] 0 0
Warszawa
Country [92] 0 0
Poland
State/province [92] 0 0
Wroclaw
Country [93] 0 0
Poland
State/province [93] 0 0
Zamosc
Country [94] 0 0
Russian Federation
State/province [94] 0 0
Ekaterinburg
Country [95] 0 0
Russian Federation
State/province [95] 0 0
Irkutsk
Country [96] 0 0
Russian Federation
State/province [96] 0 0
Moscva
Country [97] 0 0
Russian Federation
State/province [97] 0 0
Rostov-On-Don
Country [98] 0 0
Russian Federation
State/province [98] 0 0
Saint Petersburg
Country [99] 0 0
Russian Federation
State/province [99] 0 0
Ufa
Country [100] 0 0
Serbia
State/province [100] 0 0
Belgrade
Country [101] 0 0
Serbia
State/province [101] 0 0
Kragujevac
Country [102] 0 0
Serbia
State/province [102] 0 0
Nis
Country [103] 0 0
Serbia
State/province [103] 0 0
Vojvodina
Country [104] 0 0
Serbia
State/province [104] 0 0
Zemun
Country [105] 0 0
Spain
State/province [105] 0 0
Barcelona
Country [106] 0 0
Spain
State/province [106] 0 0
Girona
Country [107] 0 0
Spain
State/province [107] 0 0
Oviedo
Country [108] 0 0
Spain
State/province [108] 0 0
Sabadell
Country [109] 0 0
Spain
State/province [109] 0 0
Salamanca
Country [110] 0 0
Spain
State/province [110] 0 0
Santander
Country [111] 0 0
Spain
State/province [111] 0 0
Sevilla
Country [112] 0 0
Spain
State/province [112] 0 0
Valladolid
Country [113] 0 0
Spain
State/province [113] 0 0
Zaragoza
Country [114] 0 0
United Kingdom
State/province [114] 0 0
Bath
Country [115] 0 0
United Kingdom
State/province [115] 0 0
Bury
Country [116] 0 0
United Kingdom
State/province [116] 0 0
Kingston upon Thames
Country [117] 0 0
United Kingdom
State/province [117] 0 0
London
Country [118] 0 0
United Kingdom
State/province [118] 0 0
Southampton
Country [119] 0 0
United Kingdom
State/province [119] 0 0
Taunton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Janssen Scientific Affairs, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to compare the efficacy of treatment with ustekinumab or adalimumab in biologic naive participants with moderately-to-severely active Crohn's disease (CD) who have previously failed or were intolerant to conventional therapy (corticosteroids and/or immunomodulators, such as azathioprine, 6-mercaptopurine, or methotrexate), as measured by clinical remission at one year.
Trial website
https://clinicaltrials.gov/study/NCT03464136
Trial related presentations / publications
Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV Jr, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ; SEAVUE Study Group. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022 Jun 11;399(10342):2200-2211. doi: 10.1016/S0140-6736(22)00688-2.
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Scientific Affairs, LLC Clinical Trial
Address 0 0
Janssen Scientific Affairs, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03464136